Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Reduced by Amalgamated Bank

Amalgamated Bank trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 24.7% during the third quarter, Holdings Channel reports. The firm owned 29,444 shares of the specialty pharmaceutical company’s stock after selling 9,681 shares during the quarter. Amalgamated Bank’s holdings in Jazz Pharmaceuticals were worth $3,280,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. EverSource Wealth Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares during the period. ProShare Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 1.4% during the first quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock worth $896,000 after purchasing an additional 105 shares during the period. GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares during the period. Platinum Investment Management Ltd. raised its holdings in shares of Jazz Pharmaceuticals by 17.8% during the first quarter. Platinum Investment Management Ltd. now owns 821 shares of the specialty pharmaceutical company’s stock worth $99,000 after purchasing an additional 124 shares during the period. Finally, Arizona State Retirement System raised its holdings in shares of Jazz Pharmaceuticals by 0.8% during the second quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock worth $1,770,000 after purchasing an additional 130 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $123.61 on Friday. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The company has a 50-day moving average of $110.64 and a 200-day moving average of $109.78. The firm has a market cap of $7.63 billion, a price-to-earnings ratio of 17.41, a price-to-earnings-growth ratio of 1.40 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported $5.86 earnings per share for the quarter, beating the consensus estimate of $4.54 by $1.32. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 30.16%. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.04 billion. Analysts forecast that Jazz Pharmaceuticals plc will post 16.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. TD Cowen dropped their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday. Wells Fargo & Company dropped their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday. Finally, JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $175.00.

Insider Activity

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.